ACLX Overview
Upcoming Projects (ACLX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ACLX)
-
A Second Opinion: Looking at the new results from the Phase 3 CARTITUDE-4 study of CARVYKTI presented at ASH2024, as well as the Phase II iMMagin data on Anito-Cel from Gilead/Arcellx
Tickers: JNJ, GILD, ACLX, LEGN
Executed On: Jan 09, 2025 at 04:30 PM EST -
Looking at the new results from the Phase 3 CARTITUDE-4 study of CARVYKTI presented at ASH2024, as well as the Phase II iMMagin data on Anito-Cel from Gilead/Arcellx
Tickers: JNJ, GILD, ACLX, LEGN
Executed On: Jan 09, 2025 at 11:00 AM EST -
A Second View: Examining the potential of Arcellx’s CART-ddBCMA (anito-cel) with a focus on the Phase 1 Expansion Trial in Patients with Relapsed/Refractory Multiple Myeloma
Ticker: ACLX
Executed On: Jan 11, 2024 at 01:00 PM EST -
Examining the potential of Arcellx’s CART-ddBCMA (anito-cel) with a focus on the Phase 1 Expansion Trial in Patients with Relapsed/Refractory Multiple Myeloma
Ticker: ACLX
Executed On: Jan 10, 2024 at 11:00 AM EST -
Discussing the BCMA directed therapies in multiple myeloma with a focus on Arcellx's lead product candidate, CART-ddBCMA
Ticker: ACLX
Executed On: Oct 27, 2023 at 01:00 PM EDT
Upcoming & Overdue Catalysts (ACLX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (ACLX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
